Analysts raised the fair value estimate for BioXcel Therapeutics to approximately $18.33 per share. This represents a 31% increase over the previous valuation. The prior fair value estimate stood at $14 per share.
The revision reflects updated assumptions for revenue growth, profit margins, and future P/E multiples. This follows positive Phase 3 SERENITY At Home trial data for BXCL501. The treatment targets agitation in patients with bipolar disorders or schizophrenia.
BioXcel was also added to the Russell 3000E, Russell Microcap, and Russell Microcap Growth Benchmark indices. The company faces an August 21, 2026, deadline to secure a refinancing or capital transaction. This requirement is necessary to address outstanding debt obligations.